Background: Even in the absence of evidence on its long-term efficacy and safety, a number of patients with venous thromboembolism (VTE) receive long-term therapy with fondaparinux alone in everyday practice. Methods: We used the Registro Informatizado de Enfermedad Tromboembólica (RIETE) registry to compare the rate of VTE recurrences and major bleeding at 10 and 90 days in patients with and without cancer. For long-term therapy, fondaparinux was compared with vitamin K antagonists (VKA) in patients without cancer and with low-molecular- weight heparin (LMWH) in those with cancer Results Of 47,378 patients recruited, 46,513 were initially treated with heparin, 865 with fondaparinux. Then, 263 patients (78 with cancer) were treated for at least 3 months with fondaparinux. After propensity-score matching, there were no differences between patients receiving initial therapy with heparin or fondaparinux. Among patients with cancer, there were no differences between fondaparinux and LMWH. Among patients without cancer, the long-term use of fondaparinux was associated with an increased risk of major bleeding (3.24 % vs. 0.95 %, p < 0.05). Conclusions: An unexpected high rate of major bleeding was observed in non-cancer patients treated with longterm fondaparinux. Our small sample does not allowto derive relevant conclusions on the use of fondaparinux in cancer patients.

Fondaparinux in the initial and long-term treatment of venous thromboembolism

Amitrano M.;Amitrano M.;Dentali F.;Tufano A.;
2015-01-01

Abstract

Background: Even in the absence of evidence on its long-term efficacy and safety, a number of patients with venous thromboembolism (VTE) receive long-term therapy with fondaparinux alone in everyday practice. Methods: We used the Registro Informatizado de Enfermedad Tromboembólica (RIETE) registry to compare the rate of VTE recurrences and major bleeding at 10 and 90 days in patients with and without cancer. For long-term therapy, fondaparinux was compared with vitamin K antagonists (VKA) in patients without cancer and with low-molecular- weight heparin (LMWH) in those with cancer Results Of 47,378 patients recruited, 46,513 were initially treated with heparin, 865 with fondaparinux. Then, 263 patients (78 with cancer) were treated for at least 3 months with fondaparinux. After propensity-score matching, there were no differences between patients receiving initial therapy with heparin or fondaparinux. Among patients with cancer, there were no differences between fondaparinux and LMWH. Among patients without cancer, the long-term use of fondaparinux was associated with an increased risk of major bleeding (3.24 % vs. 0.95 %, p < 0.05). Conclusions: An unexpected high rate of major bleeding was observed in non-cancer patients treated with longterm fondaparinux. Our small sample does not allowto derive relevant conclusions on the use of fondaparinux in cancer patients.
2015
Anticoagulants; Deep vein thrombosis; Drug therapy; Fondaparinux; Pulmonary embolism; Venous thromboembolism
Pesavento, R.; Amitrano, M.; Trujillo-Santos, J.; Di Micco, P.; Mangiacapra, S.; Lopez-Jimenez, L.; Falga, C.; Garcia-Bragado, F.; Piovella, C.; Prandoni, P.; Monreal, M.; Adarraga, M. D.; Alvarado, A. V.; Arcelus, J. I.; Barba, R.; Barron, M.; Barron-Andres, B.; Bascunana, J.; Benitez, J. F.; Blanco-Molina, A.; Casado, I.; Conget, F.; Chaves, E. L.; De Ancos, C.; Del Molino, F.; Del Toro, J.; Falga, C.; Farfan, A. I.; Fernandez-Capitan, C.; Font, L.; Gallego, P.; Garcia-Bragado, F.; Gomez, V.; Gonzalez, J.; Gonzalez-Marcano, D.; Grau, E.; Guijarro, R.; Gutierrez, J.; Hernandez, L.; Hernandez-Huerta, S.; Jara-Palomares, L.; Jaras, M. J.; Jimenez, D.; Lecumberri, R.; Lobo, J. L.; Lopez-Jimenez, L.; Lopez-Montes, L.; Lopez-Reyes, R.; Lopez-Saez, J. B.; Lorente, M. A.; Lorenzo, A.; Luque, J. M.; Madridano, O.; Marchena, P. J.; Martin-Antoran, J. M.; Mellado, M.; Monreal, M.; Morales, M. V.; Nauffal, D.; Nieto, J. A.; Nunez, M. J.; Otero, R.; Pagan, B.; Pedrajas, J. M.; Peris, M. L.; Pons, I.; Porras, J. A.; Puerta, P.; Riera-Mestre, A.; Rivas, A.; Rodriguez-Davila, M. A.; Roman, P.; Rosa, V.; Ruiz-Gimenez, N.; Ruiz, J.; Samperiz, A.; Sanchez, R.; Soler, S.; Soto, M. J.; Surinach, J. M.; Tiberio, G.; Tilvan, R. M.; Tirado, R.; Trujillo-Santos, J.; Uresandi, F.; Valero, B.; Valle, R.; Vela, J.; Villalobos, A.; Malfante, P.; Matias, V.; Vivero, F.; Verhamme, P.; Peerlinck, K.; Wells, P.; Maly, R.; Hirmerova, J.; Salgado, E.; Bertoletti, L.; Bura-Riviere, A.; Moustafa, F.; Farge-Bancel, D.; Hij, A.; Mahe, I.; Merah, A.; Quere, I.; Schellong, S.; Babalis, D.; Papadakis, M.; Tzinieris, I.; Braester, A.; Brenner, B.; Tzoran, I.; Zeltser, D.; Amitrano, M.; Apollonio, A.; Barillari, G.; Cannavaccioulo, F.; Ciammaichella, M.; Dentali, F.; Di Micco, P.; Enea, I.; Guida, A.; Maida, R.; Pace, F.; Pasca, S.; Pesavento, R.; Piovella, C.; Prandoni, P.; Rota, L.; Tiraferri, E.; Tufano, A.; Visona, A.; Mesquita, P.; Ribeiro De Almeida, J. L.; Sousa, M. S.; Bosevski, M.; Zdraveska, M.; Alatri, A.; Bounameaux, H.; Calanca, L.; Mazzolai, L.; Serrano, J. C.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2147218
 Attenzione

L'Ateneo sottopone a validazione solo i file PDF allegati

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 16
  • ???jsp.display-item.citation.isi??? ND
social impact